Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 6 (2009), Issue 5 (May)

1. PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation.
   Carcinogenesis, 30(5): 824-31. [Abstract] [Full-text]
2. Dysregulation of WNT/CTNNB1 and PI3K/AKT signaling in testicular stromal cells causes granulosa cell tumor of the testis.
   Carcinogenesis, 30(5): 869-78. [Abstract] [Full-text]
3. Intrathoracic injection of paclitaxel for a patient with stage IV serous ovarian cancer: a case report.
   Cancer Chemother Pharmacol, 64(1): 169-70. [Abstract] [Full-text]
4. Behaviour of ovarian tumors of low malignant potential treated with conservative surgery.
   Eur J Surg Oncol, 35(6): 643-8. [Abstract] [Full-text]
5. Advantage of conservative surgical management of large ovarian neoplasms in adolescents.
   Fertil Steril, 91(5): 1941-4. [Abstract] [Full-text]
6. NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway.
   Oncogene, 28(18): 1941-8. [Abstract] [Full-text]
7. Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study.
   Gynecol Oncol, 113(3): 335-40. [Abstract] [Full-text]
8. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
   Gynecol Oncol, 113(3): 316-23. [Abstract] [Full-text]
9. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer.
   J Surg Oncol, 99(7): 424-7. [Abstract] [Full-text]
10. A unique case of serous psammocarcinoma of the ovary presenting with pleural effusion and manifesting psammoma body implants in the pleural cavity and pericardium.
    Gynecol Oncol, 113(3): 402-4. [Abstract] [Full-text]
11. E-cadherin expression in ovarian cancer in the laying hen, Gallus domesticus, compared to human ovarian cancer.
    Gynecol Oncol, 113(3): 362-9. [Abstract] [Full-text]
12. A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers.
    Gynecol Oncol, 113(3): 327-30. [Abstract] [Full-text]
13. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
    Gynecol Oncol, 113(3): 331-4. [Abstract] [Full-text]
14. Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study.
    Gynecol Oncol, 113(3): 341-7. [Abstract] [Full-text]
15. Precursors to pelvic serous carcinoma and their clinical implications.
    Gynecol Oncol, 113(3): 391-6. [Abstract] [Full-text]
16. Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer.
    Gynecol Oncol, 113(3): 384-90. [Abstract] [Full-text]
17. A prognostic gene expression index in ovarian cancer - validation across different independent data sets.
    J Pathol, 218(2): 273-80. [Abstract] [Full-text]
18. Tumor suppressor KAI1 affects integrin alphavbeta3-mediated ovarian cancer cell adhesion, motility, and proliferation.
    Exp Cell Res, 315(10): 1759-71. [Abstract] [Full-text]
19. Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts.
    Am J Epidemiol, 169(11): 1378-87. [Abstract] [Full-text]
20. Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma.
    Hum Pathol, 40(6): 795-806. [Abstract] [Full-text]
21. Computed tomography appearance of ovarian fibrothecomas with and without torsion.
    Acta Radiol, 50(5): 570-5. [Abstract] [Full-text]
22. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.
    Am J Physiol Regul Integr Comp Physiol, 296(6): R1716-25. [Abstract] [Full-text]
23. Familial risk for common diseases in primary care: the Family Healthware Impact Trial.
    Am J Prev Med, 36(6): 506-14. [Abstract] [Full-text]
24. The biology of ovarian cancer: new opportunities for translation.
    Nat Rev Cancer, 9(6): 415-28. [Abstract] [Full-text]
25. Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases.
    Am J Surg Pathol, 33(6): 844-53. [Abstract] [Full-text]
26. SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma.
    Am J Surg Pathol, 33(6): 894-904. [Abstract] [Full-text]
27. Prognostic significance of histological grade in clear-cell carcinoma of the ovary: a retrospective study of Korean Gynecologic Oncology Group.
    Ann Oncol, 20(6): 1032-6. [Abstract] [Full-text]
28. 14-3-3sigma expression and prognostic value in patients with epithelial ovarian carcinoma: a high throughput tissue microarray analysis.
    Eur J Surg Oncol, 35(7): 763-7. [Abstract] [Full-text]
29. Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study.
    Hum Mol Genet, 18(12): 2297-304. [Abstract] [Full-text]
30. Prophylactic bilateral oophorectomy during vaginal hysterectomy for benign pathology.
    Arch Gynecol Obstet, 280(1): 87-90. [Abstract] [Full-text]
31. Relapse and survival in early-stage ovarian cancer.
    Arch Gynecol Obstet, 280(1): 71-7. [Abstract] [Full-text]
32. An unusual case of recurrent endometrial cancer presented with isolated cervical lymph node metastasis.
    Arch Gynecol Obstet, 280(1): 153-6. [Abstract] [Full-text]
33. Primary ovarian carcinoid tumor with luteinized stromal cells.
    Arch Gynecol Obstet, 280(1): 119-21. [Abstract] [Full-text]
34. Ovarian cancer and late onset paraneoplastic cerebellar degeneration.
    Arch Gynecol Obstet, 280(1): 99-101. [Abstract] [Full-text]
35. Expression of Jun activation domain-binding protein 1 and Ser10 phosphorylated p27 protein in human epithelial ovarian carcinoma.
    J Cancer Res Clin Oncol, 135(7): 951-9. [Abstract] [Full-text]
36. Integrin beta3 down-regulates invasive features of ovarian cancer cells in SKOV3 cell subclones.
    J Cancer Res Clin Oncol, 135(7): 909-17. [Abstract] [Full-text]
37. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.
    J Clin Oncol, 27(16): 2686-91. [Abstract] [Full-text]

© 2004-2010 Ovarian Cancer Research Today. All Rights Reserved.